Zoetis/$ZTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Employees
13,800
Headquarters
Website
Zoetis Metrics
BasicAdvanced
$64B
24.66
$5.82
0.90
$1.93
1.39%
Price and volume
Market cap
$64B
Beta
0.9
52-week high
$191.94
52-week low
$139.34
Average daily volume
2.9M
Dividend rate
$1.93
Financial strength
Current ratio
1.76
Quick ratio
0.889
Long term debt to equity
109.685
Total debt to equity
137.01
Dividend payout ratio (TTM)
32.08%
Interest coverage (TTM)
16.46%
Profitability
EBITDA (TTM)
3,964
Gross margin (TTM)
71.50%
Net profit margin (TTM)
27.83%
Operating margin (TTM)
37.71%
Effective tax rate (TTM)
20.98%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
15.44%
Return on equity (TTM)
52.77%
Valuation
Price to earnings (TTM)
24.661
Price to revenue (TTM)
6.863
Price to book
12.8
Price to tangible book (TTM)
55.67
Price to free cash flow (TTM)
29.028
Free cash flow yield (TTM)
3.44%
Free cash flow per share (TTM)
4.942
Dividend yield (TTM)
1.35%
Forward dividend yield
1.39%
Growth
Revenue change (TTM)
5.27%
Earnings per share change (TTM)
14.10%
3-year revenue growth (CAGR)
5.49%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
9.68%
10-year earnings per share growth (CAGR)
21.50%
3-year dividend per share growth (CAGR)
17.47%
10-year dividend per share growth (CAGR)
19.65%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Bulls say / Bears say
Zoetis’ companion animal division posted 8% year-over-year revenue growth to $1.79 billion in Q2 2025, spurred by strong performance from Simparica Trio and the company’s pain and dermatology offerings (Reuters).
On August 5, 2025, Zoetis raised its 2025 full-year revenue forecast to $9.45 billion–$9.60 billion and lifted its adjusted EPS guidance to $6.30–$6.40, reflecting confidence in sustained demand for pet health products (Reuters).
In Q2 2025, Zoetis reported adjusted EPS of $1.76, beating the consensus estimate of $1.62—highlighting the company’s operational leverage and margin strength (Reuters).
Analysts at Stifel Nicolaus warned that rising competition from Merck’s Numelvi and Elanco’s Zenrelia and CQ is making inroads into Zoetis’s dermatology and parasiticides franchises, which together generate over 40% of the company’s total revenue (Barron's).
Stifel’s survey data pointed to stagnant international revenue for Q1 2025, hinting at possible weakness in Zoetis’s efforts to expand globally (Barron's).
Stifel’s downgrade cut Zoetis’s price target from $165 to $160, indicating they see little upside left at current valuation levels (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
Business Wire6 hours ago
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Business Wire5 days ago
Zoetis Declares Fourth Quarter 2025 Dividend
Business Wire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $64B as of October 15, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 24.66 as of October 15, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of October 15, 2025, the dividend rate is $1.932 and the yield is 1.39%. Zoetis has a payout ratio of 32.08% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment is scheduled for December 02, 2025.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.